Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

Story: 2024 C.E.  |  Last updated: April 28, 2026

A once-daily pill that physically rebuilds the neural connections destroyed by ALS has cleared a critical regulatory hurdle, earning U.S. Food and Drug Administration approval to begin Phase 2 clinical trials with ALS patients across the United States. The drug, SPG302, works differently from every approved ALS treatment currently on the market — and for the roughly 30,000 Americans living with the disease at any given time, that difference could matter enormously.

At a glance

• SPG302 pill: A once-daily oral drug developed by Spinogenix, Inc. that regenerates synapses — the gaps between neurons — to restore communication in the motor nervous system, rather than simply slowing its decline.
• Phase 1 safety trial: Early-stage testing in healthy adults in Australia confirmed the drug is well-tolerated and produces therapeutic drug levels consistent with results seen in preclinical animal studies.
• FDA IND approval: The U.S. Food and Drug Administration accepted Spinogenix’s Investigational New Drug application, clearing the legal pathway for multi-state clinical trials with ALS patients, who began receiving doses in April 2024 C.E.

Why synapse regeneration changes the equation

ALS — amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease — destroys motor neurons, the nerve cells that carry movement instructions from the brain and spinal cord to the muscles. As those neurons die, they lose the ability to communicate, and muscle control erodes progressively until breathing itself becomes impossible.

Every FDA-approved ALS drug available today works along the same basic principle: slow the disease down. None reverses it. SPG302 targets a different mechanism entirely. Rather than attempting to protect dying neurons or clear the proteins associated with cell death, it focuses on synapses — the microscopic junctions where neurons pass signals to one another. In ALS, synapse loss precedes and accelerates neuron death. SPG302 is designed to regenerate those connections before the neurons themselves are gone.

“SPG302’s unique approach to regenerating synapses offers a fundamentally different treatment modality, focusing on synapse loss, which is central to ALS,” said Stella Sarraf, Spinogenix’s CEO and founder. “Current treatments have not sufficiently met the needs of ALS patients, as slowing disease progression alone is not enough.”

What the trial will test

The Phase 2 trial will be the first rigorous test of whether SPG302 actually recovers lost function in human ALS patients — not just halts further decline. That’s an ambitious target, and the outcome is genuinely uncertain.

Dr. Merit Cudkowicz, Chair of the Massachusetts General Hospital Department of Neurology and Professor of Neurology at Harvard Medical School, sits on Spinogenix’s advisory board and has underscored what’s at stake. “ALS is a complex and varied disease, affecting cognitive and motor functions as well as speech and respiration,” she said. “This first study in people with ALS is an important step towards determining whether SPG302 helps recover lost functions in motor and cognitive symptom domains.”

The trial has already drawn significant interest from people seeking to enroll — a sign of how urgently patients and families are watching for any development that moves beyond symptom management.

The science behind the pill

Spinogenix is a clinical-stage biopharmaceutical company that emerged from research into synaptogenesis — the biological process by which synaptic connections form and reform. The science draws on decades of neuroscience research into how the brain physically repairs itself after injury, and whether those repair pathways can be pharmacologically activated in degenerative diseases like ALS.

SPG302 is a small-molecule compound, meaning it’s delivered as a simple oral pill rather than an infusion or injection. That matters practically: easier administration means better access for patients who are already managing significant physical limitations.

The FDA’s Investigational New Drug process requires manufacturers to demonstrate basic safety and propose a credible clinical protocol before trials can expand across state lines in the U.S. Spinogenix cleared that bar based largely on its Australian Phase 1 data.

A long road, but a new direction

It’s worth being honest about where this sits on the path to a treatment. Phase 2 trials test efficacy in a larger patient population, but they are not the final step. Many promising compounds that clear Phase 2 still fail in Phase 3 — the large-scale confirmatory trials required for full FDA approval. The ALS Association has documented dozens of compounds over the decades that showed early promise but did not ultimately reach patients.

What makes SPG302 genuinely notable is the mechanism, not the milestone. The idea that a pill might rebuild neural architecture — rather than simply slow its decay — represents a different theory of how ALS might be interrupted. If even partial synapse regeneration translates to measurable functional improvement in patients, it would reshape how researchers think about treating not just ALS but a range of neurodegenerative conditions.

For the estimated two to five people per 100,000 diagnosed with ALS globally each year, the arrival of a genuinely new approach — however early-stage — is something worth watching closely.

Read more

For more on this story, see: New Atlas

For more from Good News for Humankind, see:

• Alzheimer’s risk cut in half by drug in landmark prevention trial
• Ghana establishes new marine protected area at Cape Three Points
• The Good News for Humankind archive on global health

About this article

• 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
• 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
• 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
• ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.